What Olfen-100 Treats: Main Uses and Benefits

Olfen-100 is a medication containing diclofenac sodium, which belongs to a class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs). It is primarily used to manage symptoms associated with various inflammatory and painful conditions.

Primary Indications

The medication is commonly prescribed to address pain and inflammation in the following areas:

• Inflammatory Rheumatic Diseases: This includes chronic conditions such as rheumatoid arthritis and osteoarthritis, where it helps to reduce joint swelling, stiffness, and pain.
• Degenerative Joint Diseases: It is used to manage the symptomatic progression of wear-and-tear in the joints.
• Ankylosing Spondylitis: It assists in relieving the chronic inflammatory pain affecting the spine.
• Acute Musculoskeletal Disorders: Olfen-100 is used for short-term relief in cases of periarthritis (such as frozen shoulder), tendinitis, tenosynovitis, and bursitis.
• Soft Tissue Injuries: It helps in managing inflammation following sprains, strains, or dislocations.

Mechanism of Action and Benefits

Olfen-100 works by inhibiting the production of prostaglandins, which are chemicals in the body that signal pain and promote inflammation. By reducing the concentration of these substances, the medication provides several therapeutic benefits:

• Reduction of Inflammation: It decreases the swelling and redness associated with inflammatory responses.
• Pain Relief: It alleviates mild to moderately severe pain, improving the patient's comfort levels.
• Improvement in Mobility: By reducing joint stiffness and pain, it can help restore functional movement in patients with chronic rheumatic conditions.
• Fever Reduction: While not its primary use, it also possesses antipyretic properties that can help lower a fever.

Regulatory References

1. NIH MedlinePlus overview of Diclofenac

Olfen-100 is primarily intended for use in Adults, but its eligibility profile is defined by strict regulatory exclusions. Use is contraindicated for any patient with a known hypersensitivity to the active ingredient or a history of allergic-type reactions (e.g., asthma, urticaria) triggered by aspirin or other NSAIDs. The medicine is prohibited for those with active or prior gastrointestinal bleeding, ulceration, or perforation.

Patients with severe cardiac failure (NYHA Class II-IV), ischemic heart disease, cerebrovascular disease, and those recovering from Coronary Artery Bypass Graft (CABG) surgery are ineligible. It is also contraindicated in cases of severe hepatic or renal failure.

The prolonged-release capsule form is not suitable for children and adolescents. Older adults are a population requiring particular caution. The medicine is strictly contraindicated during the third trimester of pregnancy. Use during the second trimester (20–30 weeks) is restricted and limited to the lowest effective dose for the shortest duration. Use is also not recommended until conditions like dehydration are fully corrected.

Interactions with other medicines and products

Olfen-100 (Diclofenac Sodium) interactions are officially documented in regulatory sources and generally fall into two main categories: those that modify drug exposure and those that increase the risk of adverse effects (pharmacodynamic). All interaction information is descriptive and based strictly on official regulatory labels.

Officially Documented Interaction Constraints:

Interaction Type	Interacting Substance(s)	Official Regulatory Statement
Contraindicated Use	Other NSAIDs and Aspirin	Co-administration is generally not recommended due to significantly increased risk of serious gastrointestinal bleeding or ulceration.
Drug Exposure (PK)	Voriconazole (CYP2C9 Inhibitor)	Co-administration is documented to increase the systemic exposure (Cmax/AUC) of Diclofenac.
Drug Exposure (PK)	Lithium and Digoxin	Diclofenac may increase the plasma concentrations of these medicines, requiring careful monitoring.
Risk Amplification (PD)	Anticoagulants, SSRIs, Corticosteroids	Concomitant use increases the risk of serious GI bleeding due to additive anti-hemostatic effects.
Risk Amplification (PD)	Diuretics, ACE Inhibitors	Increases the potential for worsening of renal function with co-administration.

Substance and Population Notes

• Alcohol: Consumption of alcohol is documented to increase the risk of GI bleeding.
• Food: Food intake may delay the onset of absorption and reduce the peak plasma level (Cmax), but does not significantly affect the total absorbed amount (AUC).
• Elderly Patients: Interactions and their resulting adverse reactions, particularly GI bleeding, are officially documented as increased in frequency and severity in this population.

The active substance in Olfen-100 (diclofenac sodium) is classified as a non-steroidal anti-inflammatory drug (NSAID). Its primary action involves the modulation of the arachidonic acid cascade, a fundamental biochemical process. The biological target is the cyclooxygenase (COX) enzyme family, specifically both the COX-1 and COX-2 isoforms.

Diclofenac functions as a competitive, non-selective, reversible inhibitor of these enzymes. By occupying the active site, it prevents the conversion of arachidonic acid into various pro-inflammatory mediators, including prostaglandins ( PGE2) and thromboxanes. This inhibition suppresses the synthesis of these key signaling molecules. The resulting mechanistic cascade leads to the attenuation of localized vasodilation and decreased capillary permeability at the site of tissue injury. This reduction in PGE2 synthesis also constitutes the system-level physiological consequence of suppressing the pyrogenic effects mediated by the hypothalamus.

The usage of Olfen-100 follows a protocol designed to ensure the proper function of its prolonged-release design. The medicine is administered exclusively via the oral route.

Official Dosing and Frequency

For adults, the standard regimen for the Olfen-100 prolonged-release formulation is 100 mg taken once daily. This specific frequency is tied to the formulation’s design, which provides sustained release of the active ingredient. Treatment protocols emphasize utilizing the lowest effective dose for the shortest possible duration.

Administration and Preparation Protocol

The administration process requires that the prolonged-release capsule or equivalent tablet be swallowed whole with a sufficient quantity of water. It is a fundamental use constraint that the medicine must not be crushed, chewed, or divided, as this action compromises the controlled-release mechanism of the active substance. The dose is typically taken with or immediately after a meal.

Specialized Usage Principles

The use protocol includes specific provisions for certain populations. The 100 mg prolonged-release form is not deemed suitable for use in children. For older adults, instructions require using the lowest effective dose available to manage the treatment regimen. These established procedures govern the standardized approach to administering the medicine.

Research Evidence / Overview of Studies

Summary of Clinical Findings

The compound, Olfen-100 (a prolonged-release formulation of diclofenac), is a compound whose properties have been studied in research involving participants experiencing acute conditions. The compound's properties were explored in investigations of pain signaling pathways. Initial trials focused on its rapid-release formulation, diclofenac potassium, which has demonstrated consistent findings of changes in pain relief across different doses.

Efficacy in Pain and Inflammation Management

Multiple double-blind, randomized, controlled trials (RCTs) have been conducted to evaluate the compound's effect on acute nociceptive pain, such as that experienced following minor surgical procedures.

• Primary Outcome: The main measure in these studies was the change in pain intensity measured using the Visual Analog Scale (VAS) over the first 48 hours, with various levels of change in symptoms reported across multiple trials.
• Combination Therapy: Evidence from some studies has compared the combination therapy to monotherapy to assess its effect on chronic inflammation. Further trials have investigated its potential effect on the overall duration of the symptomatic phase.

Safety and Tolerability Profile

Safety evaluation has been a key component of the research, assessing adverse events (AEs), serious adverse events (SAEs), and clinical laboratory values.

• Specific Populations: The compound has been studied in individuals with mild hepatic impairment. Research has also explored its use in participants with severe kidney disease.
• Long-Term Exposure: Long-term data has been evaluated to describe the side-effect profile and to assess its suitability for prolonged use. In these studies, headache and nausea were among the adverse events most frequently reported by participants.

Drug-Drug Interactions

Research has been conducted to screen for potential interactions with commonly co-administered medications.

• Anticoagulants: Data indicated that the co-administration of diclofenac was associated with a finding of no significant change in the International Normalized Ratio (INR) among participants receiving Warfarin, though the total number of participants in this subgroup was small. The combination of NSAIDs and anticoagulants generally requires close monitoring due to increased risk of bleeding.

Common questions about Olfen-100 (FAQ)

---

Q: How long can I safely take Olfen-100?

Official regulatory guidance states that Olfen-100 is to be used at the lowest effective dose for the shortest duration necessary to control symptoms. Regulatory principles indicate the need for continued treatment is re-evaluated periodically, particularly if treatment lasts longer than four weeks. This approach is generally consistent with minimizing potential risks, especially those related to cardiovascular health.

---

Q: What is the difference between Olfen-100 and regular diclofenac?

Olfen-100 is specifically a prolonged-release capsule, also referred to as Depocaps, which is a key distinction. This prolonged-release design works to release the active ingredient (diclofenac) gradually into the system. This allows the product to maintain sustained therapeutic levels over time, unlike immediate-release (or 'regular') formulations that release the drug rapidly.

---

Q: Can I take Olfen-100 with Tylenol (acetaminophen)?

Official product information typically advises against co-administration with other non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin. Acetaminophen, known by brand names like Tylenol, is not classified as an NSAID. While some regulatory guidance suggests this combination is generally acceptable, adherence to recommended dosing limits for acetaminophen is a standard safety measure.

---

Q: What conditions or types of pain does Olfen-100 treat?

According to official regulatory documents, Olfen-100 is indicated for the relief of signs and symptoms associated with chronic inflammatory conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It is also indicated for the acute or long-term management of various other painful inflammatory states.

---

Q: How quickly does Olfen-100 start working?

Since Olfen-100 is a prolonged-release formulation, it is designed for a gradual and sustained effect rather than a rapid one. Studies indicate that the time it takes to reach maximum drug levels in the blood is delayed compared to immediate-release forms. Taking the medicine with food may cause a further delay in the start of absorption.

---

Q: What should I do if I miss a dose of Olfen-100?

Official patient information often describes a protocol where a missed dose is taken as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the general practice is to skip the missed dose entirely. The standard recommendation is to return to the regular dosing schedule and to avoid taking a double dose to compensate for a missed one.

---

Q: What is the difference between the 100 mg dose and the lower doses, like the 50 mg?

The 100 mg dose is typically designed as a prolonged-release form for once-daily use, which helps maintain steady drug levels throughout the day. Lower doses, such as 50 mg, are usually immediate-release tablets. These lower strengths may be taken multiple times a day to achieve the prescribed total daily dose.

How to Store and Dispose of Olfen-100?

---

Storage Requirements

Olfen-100 (Diclofenac Sodium prolonged-release capsules) must be stored at room temperature, specifically below 25 C (77 F). It is essential to keep the medicine from freezing and to protect it from moisture and direct light by storing it in its original container.

Shelf-Life and Child Safety

Do not use Olfen-100 after the expiry date printed on the packaging. All medicine must be stored out of the reach and sight of children.

Disposal Instructions

Discard any unused or expired Olfen-100 according to local regulatory requirements, which often include pharmacy take-back programs. Medicine must not be disposed of in wastewater or routine household trash to protect the environment.